See more : Pettenati S.A. Industria Têxtil (PTNT3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of NEXGEL, Inc. (NXGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NEXGEL, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Maintel Holdings Plc (MAI.L) Income Statement Analysis – Financial Results
- Vascon Engineers Limited (VASCONEQ.NS) Income Statement Analysis – Financial Results
- AKI India Limited (AKI.BO) Income Statement Analysis – Financial Results
- United Urban Investment Corporation (UUICF) Income Statement Analysis – Financial Results
- va-Q-tec AG (0RJD.L) Income Statement Analysis – Financial Results
NEXGEL, Inc. (NXGL)
About NEXGEL, Inc.
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.09M | 2.05M | 1.55M | 674.00K | 717.00K | 2.21M | 1.99M | 2.15M |
| Cost of Revenue | 3.47M | 1.79M | 1.54M | 965.00K | 854.00K | 1.70M | 1.85M | 2.27M |
| Gross Profit | 619.00K | 256.00K | 9.00K | -291.00K | -137.00K | 514.00K | 147.00K | -114.00K |
| Gross Profit Ratio | 15.14% | 12.50% | 0.58% | -43.18% | -19.11% | 23.23% | 7.38% | -5.30% |
| Research & Development | 103.00K | 367.00K | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.02M | 2.38M | 2.54M | 1.96M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 620.00K | 436.00K | 320.00K | 13.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.99M | 3.24M | 2.54M | 1.97M | 1.79M | 2.40M | 1.12M | 1.75M |
| Other Expenses | 0.00 | 3.00K | 13.00K | 8.00K | 0.00 | 0.00 | 0.00 | 25.00K |
| Operating Expenses | 4.10M | 3.60M | 2.58M | 1.97M | 1.79M | 2.40M | 1.12M | 1.75M |
| Cost & Expenses | 7.57M | 5.40M | 4.12M | 2.93M | 2.64M | 4.10M | 2.96M | 4.02M |
| Interest Income | 0.00 | 1.34M | 2.00M | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.00K | 1.34M | 2.00M | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 443.00K | 301.00K | 113.00K | 50.00K | 67.00K | 322.00K | 316.00K | 324.00K |
| EBITDA | -2.73M | -3.11M | -2.20M | -2.20M | -1.86M | -1.57M | -653.00K | -1.54M |
| EBITDA Ratio | -66.76% | -148.63% | -158.41% | -326.71% | -259.00% | -70.76% | -32.78% | -71.56% |
| Operating Income | -3.48M | -3.35M | -2.57M | -2.26M | -1.92M | -1.89M | -969.00K | -1.86M |
| Operating Income Ratio | -85.03% | -163.48% | -165.70% | -335.31% | -268.34% | -85.31% | -48.64% | -86.62% |
| Total Other Income/Expenses | 289.00K | -1.40M | -1.74M | -4.00K | 1.00K | 0.00 | 0.00 | 25.00K |
| Income Before Tax | -3.19M | -4.75M | -4.31M | -2.26M | -1.92M | -1.89M | -969.00K | -1.84M |
| Income Before Tax Ratio | -77.97% | -231.74% | -277.89% | -335.91% | -268.20% | -85.31% | -48.64% | -85.46% |
| Income Tax Expense | 0.00 | 1.40M | 2.00M | 18.00K | -104.86K | 160.86K | -16.00K | -63.00K |
| Net Income | -3.16M | -6.14M | -6.31M | -2.28M | -1.92M | -1.89M | -953.00K | -1.78M |
| Net Income Ratio | -77.21% | -300.00% | -406.71% | -338.58% | -268.20% | -85.31% | -47.84% | -82.53% |
| EPS | -0.56 | -1.10 | -1.13 | -0.02 | -0.14 | -0.34 | -0.17 | -0.32 |
| EPS Diluted | -0.56 | -1.10 | -1.13 | -0.02 | -0.14 | -0.34 | -0.17 | -0.32 |
| Weighted Avg Shares Out | 5.67M | 5.57M | 5.57M | 104.28M | 13.57M | 5.57M | 5.57M | 5.57M |
| Weighted Avg Shares Out (Dil) | 5.67M | 5.57M | 5.57M | 104.28M | 13.57M | 5.57M | 5.57M | 5.57M |
NEXGEL, Inc. (NXGL) Q3 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Maria Honeycutt - Account Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Adam Drapczuk - Chief Financial Officer Conference Call...
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing
NEXGEL Announces $2,000,000 Registered Direct Offering
LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into...
NEXGEL to Participate in Upcoming October Investor Conferences
LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief...
NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip...
NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer, President and Director Adam Drapczuk - Chief Financial...
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record second quarter 2024 revenue of $1.44 million and...
NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal
The 30-patient study is designed to measure the efficacy of applying NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatments
NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively
LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited revenue for...
Source: https://incomestatements.info
Category: Stock Reports